Home Tags IMGN853

Tag: IMGN853

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...

Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

ImmunoGen and Merck Evaluate Mirvetuximab Soravtansine in Combination with Pembrolizumab in...

ImmunoGen and Merck, known as MSD outside the United States and Canada, have entered into a clinical research collaboration for the assessment of ImmunoGen's...

Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...

Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...

Companion Diagnostics: Paving the Way for Personalized Medicine

There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of...
AACR Annual Meeting 2014

Refined Dosing Strategy for IMGN853 Achieves Objective

Data presented at the annual meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA. shows clinical activity with IMGN853 (ImmunoGen), an antibody drug conjugate or ADC currently in Phase I clinical testing for the treatment of folate receptor α (FRα)-positive cancers, including ovarian, endometrial, lung and other cancers, starting at doses of 3.3 mg/kg.

FEATURED